Aglaia Oncology Funds
Overview
Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions that have the potential to transform cancer prevention, diagnosis and therapy. The Aglaia team has decades of experience in cancer research and oncology drug development and has a track record in building successful biotech companies that focus on oncology drug development.
Investment Focus
- Focus on early-stage oncology drug development
- Commitment to impact investing
- Collaboration with innovators and entrepreneurs
- Emphasis on improving patient outcomes and quality of life
- Transparency and accountability in reporting social impact alongside financial performance
Portfolio Companies
Reach Aglaia Oncology Funds directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Aglaia Oncology Funds
What sectors does Aglaia Oncology Funds invest in?
Aglaia Oncology Funds invests in Healthcare, Life Sciences, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Utrecht, Netherlands. Aglaia Oncology Funds is listed as a vc in the ConnectSafely investor database.
What stage does Aglaia Oncology Funds invest at?
Aglaia Oncology Funds backs companies at Seed, Early Stage and Growth, writing cheques of 3M - 10M.
Which regions does Aglaia Oncology Funds invest in?
Aglaia Oncology Funds invests across United States, United Kingdom, Germany, France, Italy and Denmark.
What companies has Aglaia Oncology Funds invested in?
Aglaia Oncology Funds's portfolio includes argenx, OncoOne, InteRNA Technologies, MIMETAS and Mediomics.
Last updated · Source: ConnectSafely investor database
